Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
Identifieur interne : 001257 ( Istex/Curation ); précédent : 001256; suivant : 001258Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
Auteurs : Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-01.
English descriptors
- KwdEn :
Abstract
We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.
Url:
DOI: 10.1002/mds.870130112
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001257
Links to Exploration step
ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv</wicri:regionArea></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="1"><mods:affiliation>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Groningen, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Hospital, Groningen</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University of Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Science, University la Sapienza, Rome, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Science, University la Sapienza, Rome</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130112</idno><idno type="url">https://api.istex.fr/document/9B528618A0950D500A47E6F3C3B5917D43BDAB73/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001257</idno><idno type="wicri:Area/Istex/Curation">001257</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv</wicri:regionArea></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="1"><mods:affiliation>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Groningen, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Hospital, Groningen</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University of Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Science, University la Sapienza, Rome, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Science, University la Sapienza, Rome</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-01">1998-01</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="46">46</biblScope><biblScope unit="page" to="51">51</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9B528618A0950D500A47E6F3C3B5917D43BDAB73</idno><idno type="DOI">10.1002/mds.870130112</idno><idno type="ArticleID">MDS870130112</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bromocriptine</term><term>Dopamine agonist</term><term>Double‐blind, controlled study</term><term>Early Parkinson's disease</term><term>Ropinirole</term><term>Selegiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001257 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001257 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73
|texte= Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
}}
| This area was generated with Dilib version V0.6.23. |  |